× Close

The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.

Search results for: Mark R. Hanudel

Items from 1 to 7 out of 7 results

article

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

Mark J. Koury, Rajiv Agarwal, Glenn M. Chertow, Kai‐Uwe Eckardt, more

American Journal of Hematology > 97 > 9 > 1178 - 1188

Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent patients with CKD and anemia, the hypoxia‐inducible factor prolyl hydroxylase inhibitor, vadadustat, was noninferior...

article

Non-renal-Related Mechanisms of FGF23 Pathophysiology

Mark R. Hanudel, Marciana Laster, Isidro B. Salusky

Current Osteoporosis Reports > 2018 > 16 > 6 > 724-729

Purpose of Review We will review non-renal-related mechanisms of fibroblast growth factor 23 (FGF23) pathophysiology. Recent Findings FGF23 production and metabolism may be affected by many bone, mineral, and kidney factors. However, it has recently been demonstrated that other factors, such as iron status, erythropoietin, and inflammation, also affect FGF23 production and metabolism. As these non-mineral...

article

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

Mark R. Hanudel, Marciana Laster, Georgina Ramos, Barbara Gales, more

Pediatric Nephrology > 2018 > 33 > 11 > 2137-2142

Background Ferric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described. Methods This is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017...

article

Fractures and Osteomalacia in a Patient Treated With Frequent Home Hemodialysis

Mark R. Hanudel, Larry Froch, Barbara Gales, Harald Jüppner, more

American Journal of Kidney Diseases > 2017 > 70 > 3 > 445-448

Bone deformities and fractures are common consequences of renal osteodystrophy in the dialysis population. Persistent hypophosphatemia may be observed with more frequent home hemodialysis regimens, but the specific effects on the skeleton are unknown. We present a patient with end-stage renal disease treated with frequent home hemodialysis who developed severe bone pain and multiple fractures, including...

article

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder

Mark R. Hanudel, Isidro B. Salusky

Current Osteoporosis Reports > 2017 > 15 > 3 > 198-206

Purpose of Review In this paper, we review the pathogenesis and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD), especially as it relates to pediatric CKD patients. Recent Findings Disordered regulation of bone and mineral metabolism in CKD may result in fractures, skeletal deformities, and poor growth, which is especially relevant for pediatric CKD patients. Moreover, CKD-MBD...

article

Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients

Mark R. Hanudel, Katherine Wesseling-Perry, Barbara Gales, Georgina Ramos, more

Pediatric Nephrology > 2016 > 31 > 4 > 661-669

Background Fibroblast growth factor-23 (FGF23) levels are elevated in cardiopulmonary bypass (CPB)-associated acute kidney injury (AKI); however, it is unknown how much of the circulating FGF23 is intact and bioactive. Hypoxia may induce FGF23 production, yet its impact in humans is unknown. Pediatric cardiac surgery patients have both a high incidence of CPB-associated AKI and a high prevalence of...

article

Corticosteroids in recurrence of glomerular disease in renal transplantation: Do we know the right questions to ask?

Rhiana L. Lau, Mark R. Hanudel, Robert B. Ettenger

Pediatric Transplantation > 16 > 7 > 684 - 687

Filter options

Publication date

Last 3 years (1)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Keywords

CHRONIC KIDNEY DISEASE (2)
CKD-MINERAL AND BONE DISORDER (2)
FIBROBLAST GROWTH FACTOR 23 (2)
ACUTE KIDNEY INJURY (1)
ANEMIA (1)
BONE BIOPSY (1)
BONE FRACTURE (1)
CARDIAC SURGERY (1)
CASE REPORT (1)
CHILDREN (1)
CHRONIC HYPOXEMIA (1)
CKD-MBD (1)
DIALYSIS (1)
END-STAGE RENAL DISEASE (ESRD) (1)
FERRIC CITRATE (1)
FIBROBLAST GROWTH FACTOR 23 (FGF-23) (1)
FREQUENT HEMODIALYSIS (1)
HOME HEMODIALYSIS (1)
HYPOPHOSPHATEMIA (1)
IMPAIRED BONE MINERALIZATION (1)
IRON (1)
IRON DEFICIENCY (1)
OSTEOMALACIA (1)
PATHOGENESIS (1)
PEDIATRIC (1)
PEDIATRICS (1)
PHOSPHATE (1)
SERUM PHOSPHATE (1)
TREATMENT OF CKD-MBD (1)
more

Data set

Springer (4)
Wiley (2)
Elsevier (1)

Journal

© 2015 Interdisciplinary Centre for Mathematical and Computational Modelling

Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program: SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.